Cancer diagnostic company Pacific Edge has clinched a significant Singaporean hospital trial contract, in what could become its beachhead in Southeast Asia.
Under the agreement, Tan Tock Seng Hospital will trial Pacific Edge's mainstay Cx-bladder product ''on a significant number of patients'', chief executive David Darling said yesterday.
Medical tourism visitors to Singapore rose to 900,000 last year and are expected to reach 1.4million by 2018.
Although the US remains Pacific Edge's key growth opportunity, a portion of its present $35.3million, fully underwritten, capital raising is tagged for expansion into the Southeast Asian market.
''Singapore is an important beachhead market for us. Tan Tock Seng Hospital is one of a number of major hospitals in the Southeast Asian region that we are looking to partner with,'' Mr Darling said.
The trial, beginning immediately with 100 patients, allows the hospital's urology team to gain a full understanding of Cx-bladder on its patients, in its own clinical setting, Mr Darling said.
